Article
JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation.
Cell death & disease - 9 Oct 2023
Shen Jing, Liu Guiling, Qi Hongyan, Xiang Xueping, Shao Jimin
Abstract excerpt
Aberrant activation of epidermal growth factor receptor (EGFR) signaling is closely related to the development of non-small cell lung cancer (NSCLC). However, targeted EGFR therapeutics such as tyrosine kinase inhibitors (TKIs) face the challenge of EGFR mutation-mediated resistance. Here, we showed that the reduced JmjC domain-containing 5 (JMJD5) expression is negatively associated with EGFR stability and NSCLC...
Topics
- Humans
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Protein Kinase Inhibitors
- ErbB Receptors
- Signal Transduction
- Drug Resistance, Neoplasm
- Mutation
- Cell Line, Tumor
- Tumor Suppressor Proteins
- Ubiquitin-Protein Ligases